Single nucleotide variants (SNVs) are often measured in human specimens to correlate with other phenotypic variables. In general, there are two major classes of SNVs: germline mutations, which are inherited with one allele from each parent (also known as germline), and somatic mutations which are acquired at late stage of life. Germline mutations are usually used to assess the risk of developing certain diseases. Somatic mutations are often associated with tumorigenesis. Both germline and somatic mutations have been studied extensively in biomedical research. Single nucleotide polymorphisms (SNPs) describe germline mutations at population level.

The detection of SNVs can be achieved through a variety of methods, including real time polymerase chain reaction (RT-PCR), genotyping array, Sanger sequencing, and high throughput sequencing. All of these methods use genomic DNA as the input source. For example, genome wide association studies (GWAS) typically use DNA extracted from blood to infer SNPs due to the easy collection and storage of blood. Somatic mutations occur in tumor tissues and are usually identified by comparing the DNA sequences of tumor tissue to blood or adjacent normal tissue. One of the most basic assumptions of human DNA is that in the absence of somatic mutations, every cell in the body is essentially identical. A study in 2009 by Gottlieb et al. challenged this conventional paradigm by identifying three SNPs in tissues that were not present in blood [1]. This finding received great attention, while simultaneously receiving criticism for the inaccuracy of the analyses [2].

High throughput sequencing technology enables investigators to screen for SNVs in the entire genome or exome at a reasonable cost. Over the same time period, the development of RNAseq technology has replaced microarrays as the primary tool for gene expression profiling [3–6]. Unlike microarrays, RNAseq is based on high throughput sequencing technology, and thus investigators can now also examine RNA genomic sequences at a single nucleotide resolution. RNAseq technology introduces an opportunity to compare the genomic sequences of DNA and RNA at an unprecedented large scale.

RNAseq data is often thought to be a less-than-ideal source for SNV detection due to higher false positive rates [7]. The higher false positive rates can be attributed to several reasons, including higher complexity in alignment due to the RNA splicing [8], random errors introduced during reverse transcription, PCR [9] and RNA editing [9]. Numerous attempts have been made to overcome these difficulties [8, 10, 11] with only moderate success.

The differences between DNA and RNA sequences have been previously documented. For example, Li et al. [12] reported that they observed widespread differences between the RNA and DNA sequences of the same human cells. Since its publication, three other independent follow-up studies [13–15] challenged the conclusion by Li et al., arguing that the differences found by Li et al. are attributed to alignment artifacts, RNA editing, etc. To address this controversy, a more in-depth analysis of sequence data is required to discern the true differences between RNA and DNA sequences.

To date, there is no clear consensus on how much genomic difference we should expect to see between blood and tissue, and between DNA and RNA of the same subject. Answering these questions can greatly contribute to the accuracy of SNV and somatic mutation identification from multiple sources.

Genotypes were inferred by HaplotypeCaller from GATK. GATK best practice filters were used to filter out potential false positive SNPs. For the five sample-sequencing types—DNA-NB, DNA-NT, DNA-TP, RNA-NT, and RNA-TP—there are 10 possible pairs. For each pair of samples, we computed the heterozygous genotype consistency as follows: the number of consistent heterozygous genotypes between sample A and sample B divided by the total number of heterozygous genotypes in sample A or in sample B. We only considered genomic positions covered with at least 10 reads in both samples of the pair (denoted as “callable” sites). Also, we focused our study on haploid genomes (chromosome 1–22). Chromosome X, Y and mitochondrial DNA were not considered in this study.

The identification of an alternative allele at a certain genomic location is highly dependent on the depth of coverage. For a heterozygous position, the reads that support the alternative allele should ideally follow a binomial distribution,Binomial(D, 0.5). Thus, we expect to observe an alternative allele at 50% allele frequency. The probability of observing an alternative allele increases as the depth increases (Fig. 1a). As seen from this figure, setting the depth threshold at 10 allows a higher probability to observe an alternative allele. However, the distribution of the alternative-allele frequency among the reads produced by a sequencing dataset usually follows a normal distribution (Fig. 1b). Thus, there are some genotypes with extremely high or low allele frequencies that deviate from 50%. Also, during sequencing alignment, reference preferential biases can also skew the distribution of allele frequencies by 2 to 5% toward the reference allele [21]. Reference preferential bias is a type of alignment artifact, since most aligners will penalize the alignment of a read based on the number of mismatches within that read. A true SNP is counted as a mismatch during alignment, thus the aligner preferentially prefers reads with no mismatches in the alignment and slightly undercounts the reads containing alternate alleles. Furthermore, four of our five sample types are extracted from tissues in or around the tumor with acquired somatic mutation, which may contain some tumor cells carrying somatic mutaitons. For these reasons, the percentage of mutated alleles at a genomic location does not strictly follow the Binomial(D, 0.5) distribution. It is possible that only a small percentage of reads support mutated alleles. To take this into consideration, we also computed a loose genotype consistency between a pair of samples. The loose genotype consistency is computed in the same way as described above, with the exception that consistent heterozygous genotypes between samples A and B are defined as the genotypes that are consistent if they have the same alternative allele supported by at least one read that passed the quality filter (base quality >20). Thus, the actual genotype call by the HaplotypeCaller is irrelevant in this calculation.

We studied the pattern of potential RNA editing by examining the flanking sequences of the different RNA-DNA sites and the frequency of the RNA-DNA nucleotide change types. Motif analysis was carried out using HOMER [22]; cluster analysis was performed using Heatmap3 [23]. Additional annotation on the different RNA-DNA sites was done using previously reported editing sites, as described in the databases RADAR [24] and DARNED [25].

It has been proposed that single nucleotide variants, such as SNPs and somatic mutations, can be detected using RNAseq data [8, 29]. At the same time, strong evidence demonstrates large differences of detected nucleotides between DNA and RNA sequencing data [7, 12]. To further examine the genotype differences inferred from high throughput sequencing data between DNA and RNA, and among various sample sources, we designed a study to compare the genotypes obtained from five types of high throughput sequencing data that were generated from ten individuals. With thorough analysis, we observed large differences between the genotypes inferred from DNA and RNA sequencing data, which agrees with Li et al.’s findings [12]. However, Li et al. asserts these observed differences are the true differences between DNA and RNA, not accounting for differences introduced by technical errors. The study was conducted using TCGA data. Since we do not have access to the original samples, we could not perform at qPCR validation of the DNA-RNA differences.

DNA-RNA differences can be attributed to two categorical factors: biological and technical. The biological factors can be summarized as RNA editing and polyadenylation, which are a part of the natural biological process. RNA editing is the process that results in RNA nucleotide sequences that differ from the DNA template. Polyadenylation is the addition of a Poly(A) tail to the 3′ end of the mRNA during the transcription of DNA to RNA. Technical factors include reverse transcription errors, sequencing errors, and alignment errors, which are technical difficulties that we have yet to overcome. Reverse transcription errors occur during the reverse transcription from RNA to cDNA—a mandatory step for RNAseq. Sequencing errors can result from the high throughput sequencing technology, as all types of high throughput sequencing technologies have known limits and advantages. For example, Illumina’s high throughput sequencing technology is known to be sensitive to GC content [30, 31], while 454 Life Sciences’ sequencing technology produces low quality reads with long Poly (A) and (T) tracts. Alignment errors often occur while finding the best genomic locations for a read. The current alignment algorithm is largely based on the Borrows Wheeler Transformation, an algorithm that is used in computer science to compress repeated strings that contain repeated characters. Even though alignment can happen at a global level, the human genome is too complicated and contains a vast number of homologous regions, and, alignment of RNA reads to a DNA reference sequence requires that splicing of the gene exons be taken into account. All of these factors can substantially convolute the RNA alignment process and introduce potential alignment errors. Since 2001, there have been 20 reference human genomes released. Substantial improvements have been made with each new release providing more precise descriptions of the transcriptome, which in turn increases the accuracy of alignment of RNA reads. It is possible that with further advancements to the reference human genome, we will observe fewer DNA-RNA differences.

In our analysis, we also observed differences between adjacent normal tissue and blood in DNA, which are both considered to be germline. Some of these differences can be explained by tumor contamination of the adjacent normal tissue, and/or technical errors. Our results support Gottlieb’s finding that there are potential SNP differences between normal tissue and blood [1].

In conclusion, based on our analysis results, there are large differences (10%) between genotypes inferred from DNA and RNA sequencing data of the same individual. At the present time, it is difficult to assess what portion of these differences are due to biological processes and what portion of the differences are the result of technical errors. When RNAseq data is used to infer SNPs or somatic mutations, the DNA-RNA difference will result in large amounts of false positives [7], thus making RNAseq data a less than ideal source for detecting SNVs.